Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral talactoferrin plus best supportive care in refractory non-small cell lung cancer
2009-012709-20Phase 3Completed
- Sponsor
- Agennix AG
- Start
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Talactoferrin plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Started Aug 2009; status: completed.
02
Drugs
lactoferrin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-012709-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012709-20.